Drug Information

Drug General Information
Drug ID
D05RXW
Former ID
DIB010037
Drug Name
LAS-41002
Synonyms
Monovo; Corticosteroid receptor modulator (eczema, psoriasis), Almirall
Indication Eczema [ICD10:L20-L30] Phase 2 [523032]
Company
Almirall Prodesfarma SA
Target and Pathway
Target(s) Glucocorticoid receptor Target Info Modulator [544252]
KEGG Pathway Neuroactive ligand-receptor interaction
NetPath Pathway IL2 Signaling Pathway
TCR Signaling Pathway
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling
Signaling events mediated by HDAC Class II
FOXA2 and FOXA3 transcription factor networks
Glucocorticoid receptor regulatory network
Regulation of Androgen receptor activity
AP-1 transcription factor network
Reactome BMAL1:CLOCK,NPAS2 activates circadian gene expression
WikiPathways Serotonin Receptor 4/6/7 and NR3C Signaling
SIDS Susceptibility Pathways
Nuclear Receptors Meta-Pathway
Endoderm Differentiation
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
Adipogenesis
Circadian Clock
Nuclear Receptors
References
Ref 523032ClinicalTrials.gov (NCT01119313) Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema. U.S. National Institutes of Health.
Ref 544252Barrier-Restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives. Dermatol Res Pract. 2012; 2012: 923134.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.